Kymera Starts Phase 2b Asthma Trial Testing Oral STAT6 Degrader KT-621 [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
Kymera Therapeutics started dosing patients in its BREADTH Phase 2b trial of KT-621, an oral STAT6 degrader, in moderate to severe eosinophilic asthma. KT-621 is also being evaluated in parallel for atopic dermatitis as part of a broader program in Type 2 inflammatory diseases. The trial marks a key clinical milestone for Kymera Therapeutics as it advances a first in class, oral approach targeting STAT6. Kymera Therapeutics, listed as NasdaqGM:KYMR, is drawing attention as it moves KT-621 into Phase 2b while its shares trade around $72.69. The stock has returned 3.9% over the past week and 83.6% over the past year, while the three year return is 95.7% and the five year return reflects a 6.3% decline. For investors, the start of this Phase 2b asthma trial adds another data point to watch alongside Kymera's broader Type 2 inflammation pipeline. Upcoming readouts from KT-621 and its atopic dermatitis program may influence how the market views the company's oral protein degrader
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 DegraderGlobeNewswire
- Kymera Therapeutics (NASDAQ:KYMR) was given a new $133.00 price target on by analysts at Barclays PLC.MarketBeat
- Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside [Yahoo! Finance]Yahoo! Finance
KYMR
Earnings
- 11/4/25 - Miss
KYMR
Sec Filings
- 1/20/26 - Form 4
- 1/20/26 - Form 144
- 1/13/26 - Form 8-K
- KYMR's page on the SEC website